Pembrolizumab (Keytruda, Merck Sharp and Dohme) 'in combination with fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2‑negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 with a CPS ≥1'.
The dosage schedule is available in the summary of product characteristics for pembrolizumab.
The list price of pembrolizumab is £2,630 for a 100 mg per 4 ml concentrate for solution for infusion vial (excluding VAT; BNF online accessed June 2024).
The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence.